Background: Bone metastases are a common painful and debilitating consequence of castration-resistant prostate cancer (CPRC). Bone pain may predict patients' prognosis and there is a need to ...

In mouse models of prostate cancer, MTX-101 delivered twice a week reduced tumor growth, lung metastases, bone remodeling, and tissue loss induced by the presence of metastatic cancer cells in the ...

Researchers have found a way to predict which patients are likely to respond to radium-223, a standard treatment for advanced prostate cancer that has spread to the bones. By using an imaging ...

It has also been hypothesized that BMs may lie dormant behind the blood–brain barrier (BBB), where they can shelter from chemotherapeutic agents that control disease in less protected organs.

The difficulty of monitoring treatment response adds to the challenge of treating bone metastases Advanced prostate cancer often spreads to the bones, causing bone metastases. Unlike with tumours or ...

When it comes to managing prostate cancer, there is no one-size-fits-all approach. Men must consider a variety of factors ...

Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Kara Watts discussing the role ...